摘要
目的分析艾立布林治疗晚期乳腺癌的临床疗效。方法选择2020年1月至2021年11月徐州市中心医院诊治的90例蒽环/紫杉类治疗失败的人类表皮生长因子受体2(HER-2)阴性晚期乳腺癌患者,以化疗方案不同将其分成分为观察组(n=40)、对照组(n=50)。对照组接受白蛋白结合型紫杉醇治疗,观察组接受艾立布林治疗。对比2组临床疗效、血清糖类抗原153(CA153)、癌胚抗原(CEA)水平、癌症患者生存质量量表(QLQ-C30)、不良反应及预后情况。结果观察组客观缓解率(27.50%)比对照组(10.00%)高(P<0.05),观察组疾病控制率(62.50%)比对照组(40.00%)高(P<0.05)。治疗后,2组血清CA153、CEA水平均降低(P<0.05),且观察组更低(P<0.05)。治疗后,2组QLQ-C30评分均升高(P<0.05),且观察组更高(P<0.05)。2组Ⅰ~Ⅳ级中性粒细胞减少、血小板减少、贫血、恶心、外周神经病变发生率比较差异无统计学意义(P>0.05)。随访1年,观察组失访1例,对照组失访2例,观察组中位无进展生存时间(PFS)均比对照组长(P<0.05)。观察组PFS曲线优于对照组(P<0.05)。结论艾立布林治疗晚期乳腺癌近远期疗效确切,可降低血清CA153、CEA水平,提高生存质量,且安全可靠。
Objective To analysis the clinical efficacy of Eribulin in the treatment of advanced breast cancer.Methods A total of 90 advanced breast cancer patients with negative human epidermal growth factor receptor 2(HER-2)who failed the treatment of anthracycline/taxane in Xuzhou Central Hospital from January 2020 to November 2021 were selected and divided into observation group(n=40)and control group(n=50)according to different chemotherapy schemes.The patients in control group received Abraxane for injection.And the Eribulin was used in observation group.The clinical efficacy,serum carbohydrate antigen 153(CA153),carcinoembryonic antigen(CEA)levels,life quality(QLQ-C30),adverse reactions and prognosis were compared between the two groups.Results The objective remission rate of the observation group(27.50%)was higher than that of the control group(10.00%)significantly(P<0.05).And the disease control rate of the observation group was higher than that of the control group(62.5%vs.40%,P<0.05).After the treatment,the levels of serum CA153 and CEA in both groups decreased significantly(P<0.05),especially for the observation group(P<0.05).The QLQ-C30 scores of both groups increased(P<0.05),especially for the observation group(P<0.05).There was no difference in the incidence rates of grades I-IV neutropenia,thrombocytopenia,anemia,nausea and peripheral neuropathy between the two groups(P>0.05).After 1-year follow-up,1 case was lost to follow-up in the observation group and 2 cases in the control group.The median progression-free survival time(PFS)in the observation group was longer than that in the control group(P<0.05).Conclusions Eribulin has definite short-term and long-term efficacy in the treatment of advanced breast cancer,which reduces the levels of serum CA153 and CEA levels and improves the quality of life for patients.
作者
魏玲
王燕
王培
陈志敏
王群
魏卫
WEI Ling;WANG Yan;WANG Pei;CHEN Zhimin;WANG Qun;WEI Wei(Department of Medical Oncology,Xuzhou Central Hospital,Xuzhou 221009,China;Department of Breast Surgery,Xuzhou Central Hospital,Xuzhou 221029,China)
出处
《中国肿瘤外科杂志》
CAS
2023年第1期36-39,共4页
Chinese Journal of Surgical Oncology
基金
江苏省自然科学基金面上项目(SBK2018021825)。
关键词
艾立布林
晚期乳腺癌
临床疗效
安全性
Eribulin
Advanced breast cancer
Clinical efficacy
Safety
